Loading the section
Prices delayed by 15 minutes
Next earnings report: 26 October 2026 · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Revvity, Inc. trades on NYSE under the ticker RVTY. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks RVTY has traded between 81.22 $ and 166.25 $. As of 09 October 2026 the price stood 83.43 % of the way from the 52-week low to the high.
Over one year RVTY shares rose 66.86 %; over six months they rose 68.21 %. Volatility over 90 days is 38.29 %. Dividends are not included: this is price change only, as of 09 October 2026.
RVTY trades at a price-to-earnings ratio of 70.0, above the sector median of 24.8. Price to sales is 5.8, above the sector median of 3.9. Price to book is 2.3, below the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 08 October 2026 | 152.04 | 152.54 | 146.70 | 152.16 | 1M |
| 07 October 2026 | 153.03 | 156.01 | 149.25 | 153.60 | 2M |
| 06 October 2026 | 161.62 | 166.25 | 151.45 | 153.30 | 3M |
| 05 October 2026 | 151.45 | 157.45 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Revvity sells reagents and instruments for biological research and newborn screening.
The company renamed itself after selling its instruments business and concentrated on consumables: antibodies, assay kits, reagents. That is more profitable than instruments — consumables are bought continuously rather than once a decade, and a laboratory that has validated a method changes them reluctantly.
A separate line is newborn screening, mandated by law in many countries: the flow of samples does not depend on research budgets or the economic cycle. Risks: funding for science and biotech start-ups, demand in China and competition from larger suppliers of laboratory materials. The dividend is token.
Address:77 4TH AVENUE, WALTHAM, MA, 02451, US
Revvity, Inc. reported revenue of 2.9B $ and net income of 240M $ over the last four quarters. Net margin is 8.26 %. Revenue changed by +4.79 % year over year. Earnings per share are 2.08 $. Market capitalisation is 16.8B $.
RVTY has a return on equity of 3.34 %, above the sector median of −41.68 %. Return on assets is 2.00 %, above the sector median of −32.11 %. Operating margin is 12.41 %, above the sector median of −26.84 %.
| 295M |
| TXG10x Genomics, Inc. | 80.65 | +4.36 % | 269M |
| BRKRBruker Corporation | 59.00 | +1.86 % | 137M |
| AVTRAvantor, Inc. | 15.67 | +1.82 % | 130M |
| BIOBio-Rad Laboratories, Inc. | 366.16 | +1.60 % | 98M |
| 150.39 |
| 157.36 |
| 2M |
| 02 October 2026 | 149.94 | 153.38 | 148.55 | 151.53 | 1M |
| 01 October 2026 | 155.48 | 155.48 | 148.31 | 149.06 | 2M |
| 30 September 2026 | 153.49 | 158.28 | 152.81 | 152.89 | 4M |
| 29 September 2026 | 150.49 | 153.06 | 149.29 | 152.77 | 2M |
| 28 September 2026 | 148.97 | 151.05 | 148.12 | 151.02 | 2M |
| 25 September 2026 | 150.70 | 151.99 | 147.03 | 151.11 | 2M |
| 24 September 2026 | 141.79 | 152.26 | 141.79 | 150.68 | 3M |
| 23 September 2026 | 142.40 | 145.00 | 140.08 | 142.11 | 2M |
| 22 September 2026 | 143.12 | 144.77 | 141.71 | 143.31 | 3M |
| 21 September 2026 | 144.53 | 145.55 | 142.30 | 143.59 | 2M |
| 18 September 2026 | 146.50 | 146.89 | 142.45 | 143.45 | 3M |
| 17 September 2026 | 147.61 | 149.52 | 145.22 | 146.73 | 3M |
| 16 September 2026 | 140.88 | 147.50 | 140.20 | 145.73 | 3M |
| 15 September 2026 | 128.67 | 140.22 | 128.67 | 140.19 | 4M |
| 14 September 2026 | 124.69 | 128.70 | 123.95 | 128.49 | 2M |
| 11 September 2026 | 122.40 | 124.65 | 121.61 | 124.31 | 1M |